Item 1
Financial Statements
ENZO BIOCHEM, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
|
|
January 31,
2018
(unaudited)
|
|
|
July 31,
2017
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
64,468
|
|
|
$
|
64,167
|
|
Accounts receivable, net of allowances
|
|
|
14,977
|
|
|
|
15,180
|
|
Inventories
|
|
|
7,481
|
|
|
|
7,047
|
|
Prepaid expenses and other
|
|
|
2,613
|
|
|
|
2,690
|
|
Total current assets
|
|
|
89,539
|
|
|
|
89,084
|
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
7,945
|
|
|
|
7,901
|
|
Goodwill
|
|
|
7,452
|
|
|
|
7,452
|
|
Intangible assets, net
|
|
|
2,449
|
|
|
|
2,895
|
|
Other assets
|
|
|
940
|
|
|
|
333
|
|
Total assets
|
|
$
|
108,325
|
|
|
$
|
107,665
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable – trade
|
|
$
|
9,564
|
|
|
$
|
10,350
|
|
Accrued liabilities
|
|
|
9,665
|
|
|
|
6,720
|
|
Other current liabilities
|
|
|
642
|
|
|
|
740
|
|
Total current liabilities
|
|
|
19,871
|
|
|
|
17,810
|
|
|
|
|
|
|
|
|
|
|
Other liabilities
|
|
|
495
|
|
|
|
983
|
|
Total liabilities
|
|
$
|
20,366
|
|
|
$
|
18,793
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ equity:
|
|
|
|
|
|
|
|
|
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
|
|
|
—
|
|
|
|
—
|
|
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued: 47,077,840 and outstanding: 46,970,929 at January 31, 2018 and shares issued and outstanding: 46,506,176 at July 31, 2017
|
|
|
471
|
|
|
|
465
|
|
Additional paid-in capital
|
|
|
330,425
|
|
|
|
328,294
|
|
Less: Treasury stock at cost 106,911 shares at January 31, 2018 and none at July 31, 2017
|
|
|
(1,014
|
)
|
|
|
—
|
|
Accumulated deficit
|
|
|
(243,441
|
)
|
|
|
(241,900
|
)
|
Accumulated other comprehensive income
|
|
|
1,518
|
|
|
|
2,013
|
|
Total stockholders’ equity
|
|
|
87,959
|
|
|
|
88,872
|
|
Total liabilities and stockholders’ equity
|
|
$
|
108,325
|
|
|
$
|
107,665
|
|
The accompanying notes are an integral part
of these consolidated financial statements.
ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(in thousands, except per share data)
|
|
Three Months Ended
January 31,
|
|
|
Six Months Ended
January 31,
|
|
|
|
2018
|
|
|
2017
|
|
|
2018
|
|
|
2017
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical laboratory services
|
|
$
|
19,530
|
|
|
$
|
18,837
|
|
|
$
|
39,864
|
|
|
$
|
37,395
|
|
Product revenues
|
|
|
7,122
|
|
|
|
6,983
|
|
|
|
14,203
|
|
|
|
14,409
|
|
Royalty and license fee income
|
|
|
300
|
|
|
|
440
|
|
|
|
561
|
|
|
|
740
|
|
Total revenues
|
|
|
26,952
|
|
|
|
26,260
|
|
|
|
54,628
|
|
|
|
52,544
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services
|
|
|
11,730
|
|
|
|
11,052
|
|
|
|
23,772
|
|
|
|
21,948
|
|
Cost of product revenues
|
|
|
3,877
|
|
|
|
3,520
|
|
|
|
7,266
|
|
|
|
6,829
|
|
Research and development
|
|
|
812
|
|
|
|
483
|
|
|
|
1,559
|
|
|
|
1,305
|
|
Selling, general and administrative
|
|
|
11,070
|
|
|
|
11,218
|
|
|
|
21,961
|
|
|
|
22,712
|
|
Provision for uncollectible accounts receivable
|
|
|
779
|
|
|
|
679
|
|
|
|
1,593
|
|
|
|
1,348
|
|
Legal fee expense
|
|
|
1,700
|
|
|
|
370
|
|
|
|
2,131
|
|
|
|
742
|
|
Total operating costs and expenses
|
|
|
29,968
|
|
|
|
27,322
|
|
|
|
58,282
|
|
|
|
54,811
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(3,016
|
)
|
|
|
(1,062
|
)
|
|
|
(3,654
|
)
|
|
|
(2,340
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
185
|
|
|
|
79
|
|
|
|
342
|
|
|
|
125
|
|
Other
|
|
|
33
|
|
|
|
24
|
|
|
|
69
|
|
|
|
143
|
|
Foreign exchange gain (loss)
|
|
|
800
|
|
|
|
(94
|
)
|
|
|
605
|
|
|
|
(455
|
)
|
Loss before income taxes
|
|
|
(1,998
|
)
|
|
|
(1,053
|
)
|
|
|
(2,638
|
)
|
|
|
(2,527
|
)
|
Benefit for income taxes
|
|
|
1,097
|
|
|
|
—
|
|
|
|
1,097
|
|
|
|
—
|
|
Net loss
|
|
$
|
(901
|
)
|
|
$
|
(1,053
|
)
|
|
$
|
(1,541
|
)
|
|
$
|
(2,527
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
$
|
(0.02
|
)
|
|
$
|
(0.02
|
)
|
|
$
|
(0.03
|
)
|
|
$
|
(0.05
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
|
46,941
|
|
|
|
46,292
|
|
|
|
46,806
|
|
|
|
46,282
|
|
The accompanying notes are an integral part
of these consolidated financial statements.
ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)
(in thousands)
|
|
Three Months Ended
January 31,
|
|
|
Six Months Ended
January 31,
|
|
|
|
2018
|
|
|
2017
|
|
|
2018
|
|
|
2017
|
|
Net loss
|
|
$
|
(901
|
)
|
|
$
|
(1,053
|
)
|
|
$
|
(1,541
|
)
|
|
$
|
(2,527
|
)
|
Other comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustments
|
|
|
(578
|
)
|
|
|
(16
|
)
|
|
|
(495
|
)
|
|
|
238
|
|
Comprehensive loss
|
|
$
|
(1,479
|
)
|
|
$
|
(1,069
|
)
|
|
$
|
(2,036
|
)
|
|
$
|
(2,289
|
)
|
The accompanying notes are an integral part
of these consolidated financial statements.
ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
Six Months Ended January 31, 2018
(UNAUDITED)
(in thousands, except share data)
|
|
Common
Stock
Shares Issued
|
|
|
Treasury
Stock
Shares
|
|
|
Common
Stock
Amount
|
|
|
Additional
Paid-in
Capital
|
|
|
Treasury Stock
Amount
|
|
|
Accumulated
Deficit
|
|
|
Accumulated
Other
Comprehensive
Income
|
|
|
Total
Stockholders’
Equity
|
|
Balance at July 31, 2017
|
|
|
46,506,176
|
|
|
|
—
|
|
|
$
|
465
|
|
|
$
|
328,294
|
|
|
$
|
—
|
|
|
$
|
(241,900
|
)
|
|
$
|
2,013
|
|
|
$
|
88,872
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period ended January 31, 2018
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(1,541
|
)
|
|
|
—
|
|
|
|
(1,541
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cashless option exercise
|
|
|
340,898
|
|
|
|
106,911
|
|
|
|
—
|
|
|
|
1,014
|
|
|
|
(1,014
|
)
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vesting of restricted stock
|
|
|
2,062
|
|
|
|
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise of stock options
|
|
|
228,704
|
|
|
|
—
|
|
|
|
6
|
|
|
|
704
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
710
|
|
Share-based compensation charges
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
413
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
413
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustments
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(495
|
)
|
|
|
(495
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at January 31, 2018
|
|
|
47,077,840
|
|
|
|
106,911
|
|
|
$
|
471
|
|
|
$
|
330,425
|
|
|
$
|
(1,014
|
)
|
|
$
|
(243,441
|
)
|
|
$
|
1,518
|
|
|
$
|
87,959
|
|
The accompanying notes are an integral part
of these consolidated financial statements
ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(in thousands)
|
|
Six Months Ended
January 31,
|
|
|
|
2018
|
|
|
2017
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(1,541
|
)
|
|
$
|
(2,527
|
)
|
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization of property, plant and equipment
|
|
|
1,051
|
|
|
|
1,023
|
|
Amortization of intangible assets
|
|
|
484
|
|
|
|
819
|
|
Provision for uncollectible accounts receivable
|
|
|
1,593
|
|
|
|
1,348
|
|
Share-based compensation charges
|
|
|
413
|
|
|
|
392
|
|
Accrual for share-based 401(k) employer match expense
|
|
|
358
|
|
|
|
354
|
|
Foreign exchange (gain) loss
|
|
|
(595
|
)
|
|
|
420
|
|
|
|
|
|
|
|
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(1,387
|
)
|
|
|
(2,170
|
)
|
Inventories
|
|
|
(430
|
)
|
|
|
(238
|
)
|
Prepaid expenses
|
|
|
27
|
|
|
|
67
|
|
Accounts payable – trade
|
|
|
(809
|
)
|
|
|
238
|
|
Accrued liabilities, other current liabilities and other liabilities
|
|
|
2,220
|
|
|
|
(2,558
|
)
|
Other assets
|
|
|
(549
|
)
|
|
|
—
|
|
Total adjustments
|
|
|
2,376
|
|
|
|
(305
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) operating activities
|
|
|
835
|
|
|
|
(2,832
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
Capital expenditures
|
|
|
(1,066
|
)
|
|
|
(689
|
)
|
Security deposits and other
|
|
|
(10
|
)
|
|
|
2
|
|
Net cash used in investing activities
|
|
|
(1,076
|
)
|
|
|
(687
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
Proceeds from borrowings under Credit Agreement
|
|
|
—
|
|
|
|
40,694
|
|
Repayments under Credit Agreement
|
|
|
—
|
|
|
|
(42,251
|
)
|
Installment loan and capital lease obligation payments
|
|
|
(190
|
)
|
|
|
(323
|
)
|
Proceeds from exercise of stock options
|
|
|
710
|
|
|
|
71
|
|
Net cash provided by (used in) financing activities
|
|
|
520
|
|
|
|
(1,809
|
)
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
22
|
|
|
|
(22
|
)
|
|
|
|
|
|
|
|
|
|
Increase (decrease) in cash and cash equivalents
|
|
|
301
|
|
|
|
(5,350
|
)
|
Cash and cash equivalents - beginning of period
|
|
|
64,167
|
|
|
|
67,777
|
|
Cash and cash equivalents - end of period
|
|
$
|
64,468
|
|
|
$
|
67,427
|
|
The accompanying
notes are an integral part of these consolidated financial statements
.
ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
As of January 31, 2018
(Unaudited)
(Dollars in thousands, except share data)
Note 1 – Basis of Presentation
The accompanying consolidated financial statements include the
accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics and
Enzo Realty LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”.
The consolidated balance sheet as of January 31, 2018, the consolidated statements of operations and comprehensive income (loss)
for the three and six month ended January 31, 2018 and 2017 and the consolidated statement of stockholders’ equity and cash
flows for the six months ended January 31, 2018 and 2017 (the “interim statements”) are unaudited. In the opinion of
management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and
operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual
financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed
or omitted. The interim statements should be read in conjunction with the consolidated financial statements for the year ended
July 31, 2017 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange
Commission. The consolidated balance sheet at July 31, 2017 has been derived from the audited financial statements at that date.
The results of operations for the three and six months ended January 31, 2018 are not necessarily indicative of the results that
may be expected for the fiscal year ending July 31, 2018.
Effect of New Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In March 2016, the Financial Accounting Standards Board (“FASB”)
issued Accounting Standards Update (“ASU”) 2016-09,
Improvements to Employee Share-Based Payment Accounting
,
which requires all excess tax benefits or deficiencies to be recognized as income tax expense or benefit in the income statement.
In addition, excess tax benefits should be classified along with other income tax cash flows as an operating activity in the statement
of cash flows. The adoption of this new standard did not have a material impact on our consolidated financial statements. We adopted
this standard as of August 1, 2017.
Pronouncements Issued but Not Yet Adopted
In May 2014, FASB issued ASU No. 2014-09,
Revenue from
Contracts with Customers: Topic 606
. ASU 2014-09 and its amendments supersede the current revenue recognition guidance,
including industry-specific guidance. The new standard introduces a five-step model to achieve its core principle of the
entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the
consideration to which the entity expects to be entitled in exchange for those goods or services, and on transfer of control,
as opposed to transfer of risk and rewards. The standard also expands the required financial statement disclosures regarding
revenue recognition. ASU 2014-09 will be effective for our interim periods and the fiscal year beginning August 1, 2018, and
we are not early adopting. An entity can apply the revenue standard retrospectively to each prior reporting period presented
(full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at
the date of initial application in retained earnings. We expect to use the full retrospective method upon adoption. Based on
our preliminary assessment, the adoption of this ASU may result in partially or substantially all of the amounts that
have historically been classified as bad debt expense, primarily related to patient responsibility, could be considered an
implicit price concession in determining net revenues. Accordingly, we may report the estimate of uncollectible
balances associated with patient responsibility as a reduction of the transaction price and therefore as a reduction in net
revenues when historically these amounts were classified as bad debt expense within operating costs and expenses. In
addition, the adoption of this ASU will result in increased disclosure, including qualitative and quantitative disclosure
about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts from customers. However,
the adoption of this ASU is not expected to have a material impact on our financial position or cash flows.
In February 2016, FASB issued ASU No. 2016-02 –
Leases
(Topic 842)
. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease
liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or
operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective
for our fiscal year beginning August 1, 2019 including interim periods within that fiscal year. A modified retrospective transition
approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest
comparative period presented in the financial statements, with certain practical expedients available. We
believe the adoption of this standard will materially impact our
consolidated financial statements by significantly increasing our non-current assets and non-current liabilities on our consolidated
balance sheets in order to record the right of use assets and related lease liabilities for our existing operating leases.
We will recognize expense in the consolidated statement of operations
similar to current lease accounting, in the cost of sales and selling, general and administrative.
In May 2017, the FASB issued ASU 2017-09,
Compensation –
Stock Compensation (Topic 708) Scope of Modification Accounting
which provides guidance about which changes to the terms or
conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Adoption of the Standard
is required for our annual and interim periods beginning August 1, 2018 with the amendments in the update applied prospectively
to an award modified on or after the adoption date. Early adoption is permitted. We are currently evaluating the impact this new
standard will have on the consolidated financial statements.
We reviewed all other recently issued accounting pronouncements
and have concluded they are not applicable or not expected to be significant to the accounting for our operations.
Certain prior period amounts have been reclassified to conform
to the current period presentation. These reclassifications had no effect on the reported results of operations.
Concentration Risk
One provider whose programs are included in the “Third-party
payer” and “Health Maintenance Organizations” (“HMO’s”) categories represents approximately
38% and 39% of the Clinical Labs segment laboratory services revenue for the three months ended January 31, 2018 and 2017, respectively,
and 39% and 37% for the six months ended January 31, 2018 and 2017, respectively.
Note 2 – Net income (loss) per share
Basic net income (loss) per share represents net income (loss)
divided by the weighted average number of common shares outstanding during the period. As a result of the net loss for the three
and six months ended January 31, 2018 and 2017 diluted weighted average shares outstanding are the same as basic weighted average
shares outstanding, and do not include the potential common shares from stock options and unvested restricted stock because to
do so would be antidilutive.
For the three and six months ended January 31, 2018, the number
of potential common shares (“in the money options”) and unvested restricted stock excluded from the calculation of
diluted earnings per share was 719,000, and 825,000, respectively. For the three and six months ended January 31, 2017, approximately
888,000 and 804,000 weighted average stock options were excluded from the calculation of diluted weighted average shares outstanding.
For the three and six months ended January 31, 2018 there were
no outstanding “out of the money” options to purchase common shares. For the three and six months ended January 31,
2017, the effect of approximately 494,000 and 247,000 of outstanding “out of the money” options to purchase common
shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive.
Note 3 - Supplemental disclosure for statement of cash flows
For the six months ended January 31, 2018 and 2017, income taxes
paid by the Company were $15 and $996, respectively
.
For the six months ended January 31, 2018 and 2017, interest paid
by the Company was $45 and $77, respectively.
For the six months ended January 31, 2018 and 2017, the Company
financed $0 and $69 respectively, in machinery and transportation equipment under installment loans.
During the six months ended January 31, 2018 and 2017, the Company
did not enter into any capital lease agreements.
During the six months ended January 31, 2018 certain officers
of the Company exercised 340,898 stock options in non-cash transactions. The officers surrendered 106,911 shares of the Company’s
common stock to exercise the stock options. The Company recorded approximately $1,014, the market value of the surrendered shares,
as treasury stock.
Note 4 – Inventories
Inventories consist of the following:
|
|
January 31,
2018
|
|
|
July 31,
2017
|
|
Raw materials
|
|
$
|
809
|
|
|
$
|
852
|
|
Work in process
|
|
|
1,951
|
|
|
|
1,905
|
|
Finished products
|
|
|
4,721
|
|
|
|
4,290
|
|
|
|
$
|
7,481
|
|
|
$
|
7,047
|
|
Note 5 – Goodwill and intangible assets
At January 31, 2018 and July 31, 2017, the Company’s carrying
amount of goodwill, related to the Clinical Labs segment, is $7,452.
The Company’s change in the carrying amount of intangible
assets, all in the Life Sciences segment is as follows:
|
|
Gross
|
|
|
Accumulated Amortization
|
|
|
Net
|
|
July 31, 2017
|
|
$
|
27,436
|
|
|
$
|
(24,541
|
)
|
|
$
|
2,895
|
|
Amortization expense
|
|
|
—
|
|
|
|
(484
|
)
|
|
|
(484
|
)
|
Foreign currency translation
|
|
|
302
|
|
|
|
(264
|
)
|
|
|
38
|
|
January 31, 2018
|
|
$
|
27,738
|
|
|
$
|
(25,289
|
)
|
|
$
|
2,449
|
|
Intangible assets, all finite lived, consist of the following:
|
|
January 31, 2018
|
|
|
July 31, 2017
|
|
|
|
Gross
|
|
|
Accumulated
Amortization
|
|
|
Net
|
|
|
Gross
|
|
|
Accumulated
Amortization
|
|
|
Net
|
|
Patents
|
|
$
|
11,027
|
|
|
$
|
(10,964
|
)
|
|
$
|
63
|
|
|
$
|
11,027
|
|
|
$
|
(10,951
|
)
|
|
$
|
76
|
|
Customer relationships
|
|
|
12,046
|
|
|
|
(9,667
|
)
|
|
|
2,379
|
|
|
|
11,881
|
|
|
|
(9,083
|
)
|
|
|
2,798
|
|
Website and acquired content
|
|
|
1,022
|
|
|
|
(1,022
|
)
|
|
|
—
|
|
|
|
1,011
|
|
|
|
(1,011
|
)
|
|
|
—
|
|
Licensed technology and other
|
|
|
498
|
|
|
|
(491
|
)
|
|
|
7
|
|
|
|
484
|
|
|
|
(463
|
)
|
|
|
21
|
|
Trademarks
|
|
|
3,145
|
|
|
|
(3,145
|
)
|
|
|
—
|
|
|
|
3,033
|
|
|
|
(3,033
|
)
|
|
|
—
|
|
Total
|
|
$
|
27,738
|
|
|
$
|
(25,289
|
)
|
|
$
|
2,449
|
|
|
$
|
27,436
|
|
|
$
|
(24,541
|
)
|
|
$
|
2,895
|
|
At January 31, 2018, information with respect to intangibles assets
acquired is as follows:
|
|
Useful life assigned
|
|
Weighted average
remaining useful life
|
Customer relationships
|
|
8 -15 years
|
|
3 years
|
Other intangibles
|
|
10 years
|
|
2 years
|
At January 31, 2018, the weighted average remaining useful life
of intangible assets is approximately two years.
Note 6 - Loan Payable
In June 2013, the Company entered into a secured Revolving Loan
and Security Agreement (the “Credit Agreement”) among the Company and certain of its subsidiaries, with Enzo Therapeutics
as a guarantor, and MidCap Financial LLC. (formerly Healthcare Finance Group, LLC). The Credit Agreement, which expired in December
2016, provided for borrowings against eligible US receivables, as defined, of the Clinical Lab and Life Science segments up to
$8.0 million at defined eligibility percentages and provided for additional borrowings of $4.0 million for increased eligible assets.
Debt issuance costs of $281 were amortized over the life of the Credit Agreement. The Credit Agreement expired and was repaid in
full on December 7, 2016.
Note 7 – Accrued Liabilities
Accrued liabilities consist of the following:
|
|
January 31,
2018
|
|
|
July 31,
2017
|
|
Payroll, benefits, and commissions
|
|
$
|
5,217
|
|
|
$
|
4,092
|
|
Professional fees
|
|
|
825
|
|
|
|
442
|
|
Legal fee expense
|
|
|
1,558
|
|
|
|
599
|
|
Research and development
|
|
|
143
|
|
|
|
143
|
|
Other
|
|
|
1,922
|
|
|
|
1,444
|
|
|
|
$
|
9,665
|
|
|
$
|
6,720
|
|
At January 31, 2018, other accrued liabilities primarily include
$400 for a legal settlement.
Note 8 – Other Liabilities
Other liabilities consist of the following:
|
|
January 31,
2018
|
|
|
July 31,
2017
|
|
Capital lease obligations, net of short term
|
|
$
|
488
|
|
|
$
|
551
|
|
Accrued legal settlement
|
|
|
—
|
|
|
|
410
|
|
Installment loans, net of short term
|
|
|
7
|
|
|
|
22
|
|
|
|
$
|
495
|
|
|
$
|
983
|
|
As of January 31, 2018, future minimum payments under the capital
leases, net of interest of $89 aggregates $661 including a short term debt portion of $173 included in other current liabilities.
Future minimum payments under the installment loans aggregate $67, including a short term portion of $60 included in other current
liabilities.
Note 9 – Stockholders’ Equity
Controlled Equity Offering
The Company has a Controlled Equity Offering
SM
Sales
Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”). Under the
Sales Agreement, the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock,
par value $0.01 per share (the “Common Stock”). The Company pays Cantor a commission of 3.0% of the aggregate gross
proceeds received under the Sale Agreement. The Company is not obligated to make any sales of the shares under the Sales Agreement.
The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the shares subject
to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. The initial
agreement contemplated the sale of shares of the Company’s common stock having an aggregate offering price of up to $20.0
million. In December 2014, the Sales Agreement was amended in order for the Company to offer and sell additional shares of Common
Stock having an aggregate offering price of $20.0 million.
On September 1, 2017, the Company filed with the SEC a “shelf”
registration and sales agreement prospectus covering the offering, issuance and sale of our Common Stock that may be issued and
sold under the existing Sales Agreement in an aggregate amount of up to $19.15 million. A total of $150 million of securities may
be sold under this shelf registration, which was declared effective September 15, 2017.
During the six months ended January 31, 2018 and during fiscal
2017, the Company did not sell any shares of Common Stock under the Sales Agreement.
Treasury stock
During the six months ended January 31, 2018, certain officers
of the Company exercised 340,898 stock options in non-cash transactions. The officers surrendered 106,911 shares of the Company’s
common stock to exercise the stock options. The Company recorded approximately $1,014, the market value of the surrendered shares,
as treasury stock.
Share-based compensation
The Company has an incentive stock option and restricted stock
award plan (the “2005 Plan”), and a long term incentive share award plan, (the “2011 Plan”), which are
more fully described in Note 10 to the consolidated financial statements included in the Company’s Annual Report on Form
10-K for the fiscal year ended July 31, 2017. The 2011 Incentive Plan, which is the only plan from which awards may now be granted,
provides for the award to eligible employees, officers, directors, consultants and other persons of stock options, stock appreciation
rights (SARs), restricted stock, restricted stock units, performance awards, and other stock-based awards.
At the 2017 annual meeting, shareholders approved the amendment
and restatement of the 2011 Plan, including an increase in the number of shares of common stock authorized for grant under the
2011 Plan, from 3 million shares to 5 million shares.
The amounts of share-based compensation expense recognized in
the periods presented are as follows:
|
|
Three months ended
January 31,
|
|
|
Six months ended
January 31,
|
|
|
|
2018
|
|
|
2017
|
|
|
2018
|
|
|
2017
|
|
Stock options
|
|
$
|
205
|
|
|
$
|
236
|
|
|
$
|
407
|
|
|
$
|
382
|
|
Restricted stock
|
|
|
3
|
|
|
|
5
|
|
|
|
6
|
|
|
|
10
|
|
|
|
$
|
208
|
|
|
$
|
241
|
|
|
$
|
413
|
|
|
$
|
392
|
|
The following table sets forth the amount of expense related to
share-based payment arrangements included in specific line items in the accompanying statements of operations:
|
|
Three months ended
January 31,
|
|
|
Six months ended
January 31,
|
|
|
|
2018
|
|
|
2017
|
|
|
2018
|
|
|
2017
|
|
Cost of clinical laboratory services
|
|
$
|
—
|
|
|
$
|
1
|
|
|
$
|
—
|
|
|
$
|
3
|
|
Selling, general and administrative
|
|
|
208
|
|
|
|
240
|
|
|
|
413
|
|
|
|
389
|
|
|
|
$
|
208
|
|
|
$
|
241
|
|
|
$
|
413
|
|
|
$
|
392
|
|
No excess tax benefits were recognized during the six month periods
ended January 31, 2018 and 2017.
Stock Option Plans
The following table summarizes stock option activity during the
six month period ended January 31, 2018:
|
|
Options
|
|
|
Weighted
Average
Exercise
Price
|
|
|
Weighted
Average
Remaining
Contractual
Term
|
|
Aggregate
Intrinsic
Value (000s)
|
|
Outstanding at July 31, 2017
|
|
|
2,130,995
|
|
|
$
|
4.26
|
|
|
|
|
|
|
|
Awarded
|
|
|
112,580
|
|
|
$
|
8.36
|
|
|
|
|
|
|
|
Exercised
|
|
|
(569,602
|
)
|
|
$
|
3.02
|
|
|
|
|
$
|
5,594
|
|
Cancelled or expired
|
|
|
(26,334
|
)
|
|
$
|
5.82
|
|
|
|
|
|
|
|
Outstanding at end of period
|
|
|
1,647,639
|
|
|
$
|
4.95
|
|
|
2.8 years
|
|
$
|
6,785
|
|
Exercisable at end of period
|
|
|
1,109,811
|
|
|
$
|
4.18
|
|
|
1.4 years
|
|
$
|
3,533
|
|
As of January 31, 2018, the total future compensation cost related
to non-vested options, not yet recognized in the statements of operations, was $1.0 million and the weighted average period over
which the remaining expense of these awards is expected to be recognized is fifteen months.
The intrinsic value of in the money stock option awards at the
end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise
price multiplied by the number of options.
Restricted Stock Awards
A summary of the activity pursuant to the Company’s unvested
restricted stock awards for the six months ended January 31, 2018 is as follows:
|
|
Awards
|
|
|
Weighted
Average
Award Price
|
|
Outstanding at July 31, 2017
|
|
|
7,436
|
|
|
$
|
4.45
|
|
Awarded
|
|
|
—
|
|
|
|
—
|
|
Vested
|
|
|
(2,062
|
)
|
|
$
|
(5.92
|
)
|
Forfeited
|
|
|
—
|
|
|
|
—
|
|
Unvested at end of period
|
|
|
5,374
|
|
|
$
|
3.23
|
|
The fair value of a restricted stock award is determined based
on the closing stock price on the award date. As of January 31, 2018, there was approximately $0.1 million of unrecognized compensation
cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of approximately
twenty two months.
The fair value of the awards that vested during the six months
ended January 31, 2018 and 2017 was $21 and $8, respectively.
The total number of shares available for grant as equity awards
from the 2011 Incentive Plan is approximately 2,263,400 shares as of January 31, 2018.
Note 10 – Income taxes
On December 22, 2017, legislation commonly known as the Tax Cuts
and Jobs Act of 2017 (the “Act”) was signed into law making significant changes to the Internal Revenue Code. Changes
include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December
31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition
tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017.
The Company calculated its best estimate of the impact of the
Act in accordance with its understanding of the Act and guidance available as of the date of this filing and recorded $1.1 million
as an income tax benefit in the three months ended January 31, 2018, the period in which the legislation was enacted, related to
a credit for alternative minimum taxes (AMT) paid in prior periods. A provisional amount related to the remeasurement of certain
deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future was fully offset by
an equivalent adjustment to the deferred tax valuation allowance. No provisional amount related to the one-time transition tax
on the mandatory deemed repatriation of foreign earnings was deemed necessary.
On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB
118”) was issued to address the application of US GAAP in situations when a registrant does not have the necessary information
available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax
effects of the Act. In accordance with SAB 118, the Company has determined that the $1.1 million income tax benefit, which relates
to the AMT credit, is a provisional amount and a reasonable estimate at January 31, 2018.
The Company’s effective tax rate benefit for the three and
six months ended January 31, 2018 was 54.9% and 41.6%, respectfully and was based on the refundable federal AMT credit. There was
no tax provision for the 2017 periods. The Company’s effective tax rate for all periods differed from the expected net operating
loss carryforward benefit at the U.S. federal statutory rate primarily due to the inability to recognize such benefit. The carryforward
benefit cannot be recognized because of uncertainties relating to future taxable income in terms of both its timing and its sufficiency,
which would enable the Company to realize the federal carryforward benefit.
Note 11 – Segment reporting
The Company has three reportable segments: Clinical Labs, Life
Sciences, and Therapeutics. The Clinical Labs segment provides diagnostic services to the health care community. The Life Sciences
segment develops, manufactures, and markets products to research and pharmaceutical customers. The Therapeutic segment conducts
research and development activities for therapeutic drug candidates.
The Company evaluates segment performance based on segment income
(loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate
general and administrative costs which are not allocable to the three reportable segments. Legal fee expense incurred to defend
the Company’s intellectual property and other general corporate matters is considered a component of the Other segment. Legal
fee expense specific to other segments’ activities has been allocated to those segments. When recognized, legal settlements,
net represents activities for which royalties would have been received by the Company’s Life Sciences
segment had the Company
had agreements in place with plaintiffs for the patents or products covered by the settlements.
Management of the Company assesses assets on a consolidated basis
only and, therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies
of the reportable segments are the same as those described in the summary of significant accounting policies contained in the Company’s
Annual Report on Form 10-K for the year ended July 31, 2017.
The following financial information represents the operating results
of the reportable segments of the Company:
Three months ended January 31, 2018
|
|
Clinical
Labs
|
|
|
Life
Sciences
|
|
|
Therapeutics
|
|
|
Other
|
|
|
Consolidated
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical laboratory services
|
|
$
|
19,530
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
$
|
19,530
|
|
Product revenues
|
|
|
—
|
|
|
$
|
7,122
|
|
|
|
—
|
|
|
|
—
|
|
|
|
7,122
|
|
Royalty and license fee income
|
|
|
—
|
|
|
|
300
|
|
|
|
—
|
|
|
|
—
|
|
|
|
300
|
|
|
|
|
19,530
|
|
|
|
7,422
|
|
|
|
—
|
|
|
|
—
|
|
|
|
26,952
|
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services
|
|
|
11,730
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
11,730
|
|
Cost of product revenues
|
|
|
—
|
|
|
|
3,877
|
|
|
|
—
|
|
|
|
—
|
|
|
|
3,877
|
|
Research and development
|
|
|
—
|
|
|
|
591
|
|
|
$
|
221
|
|
|
|
—
|
|
|
|
812
|
|
Selling, general and administrative
|
|
|
6,107
|
|
|
|
2,899
|
|
|
|
—
|
|
|
$
|
2,064
|
|
|
|
11,070
|
|
Provision for uncollectible accounts receivable
|
|
|
800
|
|
|
|
(21
|
)
|
|
|
—
|
|
|
|
—
|
|
|
|
779
|
|
Legal fee expense
|
|
|
8
|
|
|
|
25
|
|
|
|
—
|
|
|
|
1,667
|
|
|
|
1,700
|
|
Total operating costs and expenses
|
|
|
18,645
|
|
|
|
7,371
|
|
|
|
221
|
|
|
|
3,731
|
|
|
|
29,968
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
885
|
|
|
|
51
|
|
|
|
(221
|
)
|
|
|
(3,731
|
)
|
|
|
(3,016
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
(23
|
)
|
|
|
11
|
|
|
|
—
|
|
|
|
197
|
|
|
|
185
|
|
Other
|
|
|
3
|
|
|
|
1
|
|
|
|
—
|
|
|
|
29
|
|
|
|
33
|
|
Foreign exchange gain
|
|
|
—
|
|
|
|
800
|
|
|
|
—
|
|
|
|
—
|
|
|
|
800
|
|
Income (loss) before income taxes
|
|
$
|
865
|
|
|
$
|
863
|
|
|
$
|
(221
|
)
|
|
$
|
(3,505
|
)
|
|
$
|
(1,998
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization included above
|
|
$
|
413
|
|
|
$
|
355
|
|
|
$
|
—
|
|
|
$
|
18
|
|
|
$
|
786
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation included in above:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
28
|
|
|
$
|
21
|
|
|
|
—
|
|
|
$
|
159
|
|
|
|
208
|
|
Total
|
|
$
|
28
|
|
|
$
|
21
|
|
|
$
|
—
|
|
|
$
|
159
|
|
|
$
|
208
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures
|
|
$
|
576
|
|
|
$
|
28
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
604
|
|
Three months ended January 31, 2017
|
|
Clinical
Labs
|
|
|
Life
Sciences
|
|
|
Therapeutics
|
|
|
Other
|
|
|
Consolidated
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical laboratory services
|
|
$
|
18,837
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
$
|
18,837
|
|
Product revenues
|
|
|
—
|
|
|
$
|
6,983
|
|
|
|
—
|
|
|
|
—
|
|
|
|
6,983
|
|
Royalty and license fee income
|
|
|
—
|
|
|
|
440
|
|
|
|
—
|
|
|
|
—
|
|
|
|
440
|
|
|
|
|
18,837
|
|
|
|
7,423
|
|
|
|
—
|
|
|
|
—
|
|
|
|
26,260
|
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services
|
|
|
11,052
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
11,052
|
|
Cost of product revenues
|
|
|
—
|
|
|
|
3,520
|
|
|
|
—
|
|
|
|
—
|
|
|
|
3,520
|
|
Research and development
|
|
|
—
|
|
|
|
516
|
|
|
$
|
(33
|
)
|
|
|
—
|
|
|
|
483
|
|
Selling, general and administrative
|
|
|
5,897
|
|
|
|
2,905
|
|
|
|
—
|
|
|
$
|
2,416
|
|
|
|
11,218
|
|
Provision for uncollectible accounts receivable
|
|
|
594
|
|
|
|
85
|
|
|
|
—
|
|
|
|
—
|
|
|
|
679
|
|
Legal fee expense
|
|
|
49
|
|
|
|
16
|
|
|
|
—
|
|
|
|
305
|
|
|
|
370
|
|
Total operating costs and expenses
|
|
|
17,592
|
|
|
|
7,042
|
|
|
|
(33
|
)
|
|
|
2,721
|
|
|
|
27,322
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
1,245
|
|
|
|
381
|
|
|
|
33
|
|
|
|
(2,721
|
)
|
|
|
(1,062
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
(28
|
)
|
|
|
12
|
|
|
|
—
|
|
|
|
95
|
|
|
|
79
|
|
Other
|
|
|
17
|
|
|
|
—
|
|
|
|
—
|
|
|
|
7
|
|
|
|
24
|
|
Foreign exchange loss
|
|
|
—
|
|
|
|
(94
|
)
|
|
|
—
|
|
|
|
—
|
|
|
|
(94
|
)
|
Income (loss) before income taxes
|
|
$
|
1,234
|
|
|
$
|
299
|
|
|
$
|
33
|
|
|
$
|
(2,619
|
)
|
|
$
|
(1,053
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization included above
|
|
$
|
394
|
|
|
$
|
501
|
|
|
$
|
—
|
|
|
$
|
20
|
|
|
$
|
915
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation included in above:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services
|
|
$
|
1
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
$
|
1
|
|
Selling, general and administrative
|
|
|
23
|
|
|
$
|
15
|
|
|
|
—
|
|
|
$
|
202
|
|
|
|
240
|
|
Total
|
|
$
|
24
|
|
|
$
|
15
|
|
|
$
|
—
|
|
|
$
|
202
|
|
|
$
|
241
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures
|
|
$
|
175
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
175
|
|
Six months ended January 31, 2018
|
|
Clinical
Labs
|
|
|
Life
Sciences
|
|
|
Therapeutics
|
|
|
Other
|
|
|
Consolidated
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical laboratory services
|
|
$
|
39,864
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
$
|
39,864
|
|
Product revenues
|
|
|
—
|
|
|
$
|
14,203
|
|
|
|
—
|
|
|
|
—
|
|
|
|
14,203
|
|
Royalty and license fee income
|
|
|
—
|
|
|
|
561
|
|
|
|
—
|
|
|
|
—
|
|
|
|
561
|
|
|
|
|
39,864
|
|
|
|
14,764
|
|
|
|
—
|
|
|
|
—
|
|
|
|
54,628
|
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services
|
|
|
23,772
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
23,772
|
|
Cost of product revenues
|
|
|
—
|
|
|
|
7,266
|
|
|
|
—
|
|
|
|
—
|
|
|
|
7,266
|
|
Research and development
|
|
|
—
|
|
|
|
1,114
|
|
|
$
|
445
|
|
|
|
—
|
|
|
|
1,559
|
|
Selling, general and administrative
|
|
|
12,202
|
|
|
|
5,513
|
|
|
|
—
|
|
|
$
|
4,246
|
|
|
|
21,961
|
|
Provision for uncollectible accounts receivable
|
|
|
1,600
|
|
|
|
(7
|
)
|
|
|
—
|
|
|
|
—
|
|
|
|
1,593
|
|
Legal fee expense
|
|
|
21
|
|
|
|
28
|
|
|
|
—
|
|
|
|
2,082
|
|
|
|
2,131
|
|
Total operating costs and expenses
|
|
|
37,595
|
|
|
|
13,914
|
|
|
|
445
|
|
|
|
6,328
|
|
|
|
58,282
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
2,269
|
|
|
|
850
|
|
|
|
(445
|
)
|
|
|
(6,328
|
)
|
|
|
(3,654
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
(48
|
)
|
|
|
23
|
|
|
|
—
|
|
|
|
367
|
|
|
|
342
|
|
Other
|
|
|
17
|
|
|
|
8
|
|
|
|
—
|
|
|
|
44
|
|
|
|
69
|
|
Foreign exchange gain
|
|
|
—
|
|
|
|
605
|
|
|
|
—
|
|
|
|
—
|
|
|
|
605
|
|
Income (loss) before income taxes
|
|
$
|
2,238
|
|
|
$
|
1,486
|
|
|
$
|
(445
|
)
|
|
$
|
(5,917
|
)
|
|
$
|
(2,638
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization included above
|
|
$
|
817
|
|
|
$
|
681
|
|
|
$
|
—
|
|
|
$
|
37
|
|
|
$
|
1,535
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation included in above:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
60
|
|
|
$
|
44
|
|
|
|
—
|
|
|
$
|
309
|
|
|
|
413
|
|
Total
|
|
$
|
60
|
|
|
$
|
44
|
|
|
$
|
—
|
|
|
$
|
309
|
|
|
$
|
413
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures
|
|
$
|
994
|
|
|
$
|
72
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,066
|
|
Six months ended January 31, 2017
|
|
Clinical
Labs
|
|
|
Life
Sciences
|
|
|
Therapeutics
|
|
|
Other
|
|
|
Consolidated
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical laboratory services
|
|
$
|
37,395
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
$
|
37,395
|
|
Product revenues
|
|
|
—
|
|
|
$
|
14,409
|
|
|
|
—
|
|
|
|
—
|
|
|
|
14,409
|
|
Royalty and license fee income
|
|
|
—
|
|
|
|
740
|
|
|
|
—
|
|
|
|
—
|
|
|
|
740
|
|
|
|
|
37,395
|
|
|
|
15,149
|
|
|
|
—
|
|
|
|
—
|
|
|
|
52,544
|
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services
|
|
|
21,948
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
21,948
|
|
Cost of product revenues
|
|
|
—
|
|
|
|
6,829
|
|
|
|
—
|
|
|
|
—
|
|
|
|
6,829
|
|
Research and development
|
|
|
—
|
|
|
|
1,143
|
|
|
$
|
162
|
|
|
|
—
|
|
|
|
1,305
|
|
Selling, general and administrative
|
|
|
11,849
|
|
|
|
5,851
|
|
|
|
—
|
|
|
$
|
5,012
|
|
|
|
22,712
|
|
Provision for uncollectible accounts receivable
|
|
|
1,260
|
|
|
|
88
|
|
|
|
—
|
|
|
|
—
|
|
|
|
1,348
|
|
Legal fee expense
|
|
|
101
|
|
|
|
28
|
|
|
|
—
|
|
|
|
613
|
|
|
|
742
|
|
Total operating costs and expenses
|
|
|
35,158
|
|
|
|
13,939
|
|
|
|
162
|
|
|
|
5,625
|
|
|
|
54,884
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
2,237
|
|
|
|
1,210
|
|
|
|
(162
|
)
|
|
|
(5,625
|
)
|
|
|
(2,340
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
(57
|
)
|
|
|
22
|
|
|
|
—
|
|
|
|
160
|
|
|
|
125
|
|
Other
|
|
|
119
|
|
|
|
—
|
|
|
|
—
|
|
|
|
24
|
|
|
|
143
|
|
Foreign exchange loss
|
|
|
—
|
|
|
|
(455
|
)
|
|
|
—
|
|
|
|
—
|
|
|
|
(455
|
)
|
Income (loss) before income taxes
|
|
$
|
2,299
|
|
|
$
|
777
|
|
|
$
|
(162
|
)
|
|
$
|
(5,441
|
)
|
|
$
|
(2,527
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization included above
|
|
$
|
795
|
|
|
$
|
1,009
|
|
|
$
|
—
|
|
|
$
|
38
|
|
|
$
|
1,842
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation included in above:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services
|
|
$
|
3
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
$
|
3
|
|
Selling, general and administrative
|
|
|
40
|
|
|
$
|
26
|
|
|
|
—
|
|
|
$
|
323
|
|
|
|
389
|
|
Total
|
|
$
|
43
|
|
|
$
|
26
|
|
|
$
|
—
|
|
|
$
|
323
|
|
|
$
|
392
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures
|
|
$
|
587
|
|
|
$
|
102
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
689
|
|
Note 12 – Contingencies
The Company is engaged in litigation in the United States District
Court for the Southern District of New York against Roche Diagnostic GmbH and its related company Roche Molecular Systems, Inc.
(“Roche”), as declaratory judgment defendant. This case was commenced in May 2004. Roche seeks a declaratory judgment
of non-breach of contract and patent invalidity against the Company. Roche has also asserted tort claims against the Company. The
Company has asserted breach of contract and patent infringement causes of action against Roche. There has been extensive discovery
in the case. In 2011, Roche moved for summary judgment of non-infringement regarding the Company’s patent claims. In 2012,
the motion was granted in part and denied in part. In December 2012, Roche moved for summary judgment on the Company’s non-patent
claims. Additional discovery was taken and the Company responded to the motions in May 2013. In December 2013, the Court granted
in part and denied in part Roche’s summary judgment motion. In October 2014, the Court ordered that damages discovery concerning
the Company’s remaining contract and patent claims and Roche’s claims should be completed by the end of January 2015,
and expert discovery should be completed following the Court’s not-yet-issued claim construction ruling concerning the Company’s
patent infringement claim against Roche. Roche dropped its tort claims during damages discovery. On October 2, 2017, the Court
issued its claim construction ruling. On December 21, 2017, the Court issued a revised scheduling order which requires the completion
of expert discovery by April 13, 2018 and schedules a conference on May 31, 2018 what will function as a pre-trial conference or
a pre-motion conference. The Company and Enzo Life Sciences intend to vigorously press their remaining claims and contest the claims
against them.
As of January 31, 2018, there are seven pending cases originally
brought by the Company in the United States District Court for the District of Delaware (“the Court”) alleging patent
infringement against various companies. On June 28, 2017, the Court issued an opinion in the Gen-Probe case, granting Gen-Probe’s
motion for summary judgment that the asserted claims of the ’180 patent are invalid for nonenablement. The Court entered
final judgment of invalidity of the asserted claims of the ‘180 patent on July 19, 2017 in the Gen-Probe and Hologic cases.
The Court entered partial final judgment of invalidity of the asserted claims of the ‘180 patent and stayed the remainder
of the cases in the Becton Dickinson and Roche cases on July 31, 2017 and August 2, 2017, respectively. The Company filed
notices of appeal in each of the Gen-Probe, Hologic, Becton Dickinson, and Roche cases, which were docketed by the United States
Court of Appeals for the Federal Circuit (“Federal Circuit”). In the Abbott case, the parties agreed that the
Court’s summary judgment ruling in the Gen-Probe case invalidated all of the ’180 patent claims asserted against the
Abbott Defendants. On August 15, 2017, the Court granted Abbott’s motion for summary judgment that the asserted claims
of the ’405 patent are invalid for nonenablement. On September 1, 2017, the Court entered final judgment of invalidity
of the asserted claims of the ‘180 and ‘405 patents for nonenablement in the Abbott case. Enzo subsequently filed
a notice of appeal in the Abbott case on September 14, 2017. The Federal Circuit docketed the appeal on September 15, 2017.
The Federal Circuit consolidated the appeals from the Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche litigations (“Consolidated
Appeals”). We disagree with the Court’s invalidity decisions regarding the ‘180 and ‘405 patents
in the pending cases as set forth in our opening brief in the Consolidated Appeals pending in the Federal Circuit filed on November
28, 2017. In the Consolidated Appeals, we have asked the Federal Circuit to reverse the Court’s grants of final and
summary judgment of invalidity of the asserted claims of the ‘180 and ‘405 patents and to remand the cases against
Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche to the Court. The responsive briefs from Abbott, Becton Dickinson, Gen-Probe,
Hologic, and Roche in the Consolidated Appeals are due to be filed on March 9, 2018. In the other two cases involving Hologic,
one of the cases is stayed, while the other case is proceeding under the Court’s scheduling order with fact and expert discovery
deadlines through September 2018, a summary judgment hearing date in April 2019, and a trial date in September 2019. The
Court granted Enzo’s motion to amend its complaint to add two new defendants, Grifols Diagnostic Solutions, Inc. and Grifols,
S.A, to that case. Grifols, S.A. has moved to dismiss for lack of personal jurisdiction; briefing on that motion is complete but
the Court has not set a date for oral argument.
There can be no assurance that the Company will be successful
in these litigations. Even if the Company is not successful, management does not believe that there will be a significant adverse
monetary impact on the Company.
The Company is party to other claims, legal actions, complaints,
and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately
result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial
position or results of operations
Item 2. Management’s Discussion and Analysis of Financial
Condition and Results of Operations
The following discussion of our financial condition and results
of operations should be read in conjunction with our consolidated financial statements and related notes and other information
included elsewhere in this Quarterly Report on Form 10-Q.
Forward-Looking Statements
Our disclosure and analysis in this report, including but not
limited to the information discussed in this Item 2, contain forward-looking information about our Company’s financial results
and estimates, business prospects and products in research and development that involve substantial risks and uncertainties. From
time to time, we also may provide oral or written forward-looking statements in other materials we release to the public. Forward-looking
statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they
do not relate strictly to historic or current facts. They use words such as “anticipate”, “estimate”, “expect”,
“project”, “intend”, “plan”, “believe”, “will”, and other words and
terms of similar meaning in connection with any discussion of future operations or financial performance.
In particular, these include statements relating to future
actions, prospective products or product approvals, future performance or results of current and anticipated products, sales
efforts, expenses, interest rates, foreign currency rates, intellectual property matters, the outcome of contingencies, such
as legal proceedings, and financial results. We cannot guarantee that any forward-looking statement will be realized,
although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks,
uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying
assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or
projected. As a result, investors are cautioned not to place undue reliance on any of our forward-looking statements.
Investors should bear this in mind as they consider forward-looking statements. We do not assume any obligation to update or
revise any forward-looking statement that we make, even if new information becomes available or other events occur in the
future. We are also affected by other factors that may be identified from time to time in our filings with the Securities and
Exchange Commission, some of which are set forth in Item 1A - Risk Factors in our Form 10-K filing for the July 31, 2017
fiscal year. You are advised to consult any further disclosures we make on related subjects in our Forms 10-Q, 8-K and 10-K
reports to the Securities and Exchange Commission. Although we have attempted to provide a list of important factors which
may affect our business, investors are cautioned that other factors may prove to be important in the future and could affect
our operating results.
You should understand that it is not possible to predict or identify
all such factors or to assess the impact of each factor or combination of factors on our business. Consequently, you should not
consider any such list to be a complete set of all potential risks or uncertainties.
Overview
Enzo Biochem, Inc. (the “Company” “we”,
“our” or “Enzo”) is an integrated diagnostic bioscience company focusing on delivering and applying advanced
technology capabilities to produce affordable reliable products and services to allow our customers to meet their clinical needs.
We develop, manufacture and sell our proprietary technology solutions and platforms to clinical laboratories, specialty clinics
and researchers and physicians globally. Enzo’s structure and business strategy represent the culmination of years of
extensive planning and work. The Company now has the unique ability to offer low cost, high performance products and services
in molecular diagnostics, which ideally positions it to capitalize on the reimbursement pressures facing diagnostic labs.
Our pioneering work in genomic analysis coupled with our extensive patent estate and enabling platforms have positioned the Company
to continue to play an important role in the rapidly growing molecular medicine marketplaces.
Enzo technology solutions and platforms and unique operational
structure are designed to reduce overall healthcare costs for both government and private insurers.
Our
proprietary technology platforms reduces our customers’ need for multiple, specialized instruments, and offer a variety of high
throughput capabilities together with a demonstrated high level of accuracy and reproducibility. Our genetic test panels are focused
on large and growing markets primarily in the areas of personalized medicine, women’s health, infectious diseases and genetic disorders.
For example, our AMPIPROBE® technology platform can lead
to the development of an entire line of nucleic acid clinical products that can allow laboratories to offer a complete menu of
services at a cost that allows them to enjoy an acceptable margin. Our technology solutions provide tools to physicians, clinicians
and other health care providers to improve detection, treatment and monitoring of a broad spectrum of diseases and conditions.
In addition, reduced patient to physician office visits translates into lower healthcare processing costs and greater patient
services.
In the course of our research and development activities, we
have built a substantial portfolio of intellectual property assets, comprised of 336 issued patents worldwide, and over 151 pending
patent applications, along with extensive enabling technologies and platforms.
Below are brief descriptions of each of our operating segments
(See Note 10 in the Notes to Consolidated Financial Statements):
Enzo Clinical Labs
is a clinical reference laboratory
providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The
Company believes having a CLIA-certified and a College of American Pathologists (“CAP”) accredited medical laboratory
located in New York provides us the opportunity to more rapidly introduce cutting edge products and services to the clinical marketplace.
Enzo Clinical Labs offers an extensive menu of molecular and other clinical laboratory tests and procedures used in patient care
by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition.
Our laboratory is equipped with state-of-the-art communication and connectivity solutions enabling the rapid transmission, analysis
and interpretation of generated data. We operate a full service clinical laboratory in Farmingdale, New York, a network of over
30 patient service centers throughout New York, New Jersey and expanding into Connecticut, a free standing “STAT” or
rapid response laboratory in New York City and a full service phlebotomy, in-house logistics department, and an information technology
department. Given our license in New York State, we are able to offer testing services to clinical laboratories and physicians
in the majority of states nationwide.
Enzo Life Sciences
manufactures, develops and markets
products and tools to clinical research, drug development and bioscience research customers worldwide. Underpinned by broad technological
capabilities, Enzo Life Sciences has developed proprietary products used in the identification of genomic information by laboratories
around the world. Information regarding our technologies can be found in the “Core Technologies” section (See Form
10K for the fiscal year ended July, 31, 2017). We are internationally recognized and acknowledged as a leader in the development,
manufacturing validation and commercialization of numerous products serving not only the clinical research market but life sciences
researchers in the fields of cellular analysis and drug discovery, among others. Our operations are supported by global operations
allowing for the efficient marketing and delivery of our products around the world.
Enzo Therapeutics
is a biopharmaceutical venture
that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many
of which are derived from the pioneering work of Enzo Life Sciences. Enzo Therapeutics has focused its efforts on developing treatment
regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects.
This focus has generated a clinical and preclinical pipeline, as well as more than 101 patents and patent applications.
Results of Operations
Three months ended January 31, 2018 compared to January 31, 2017
(in 000s)
Comparative Financial Data for the Three Months Ended January
31,
|
|
2018
|
|
|
2017
|
|
|
Increase
(Decrease)
|
|
|
%
Change
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical laboratory services
|
|
$
|
19,530
|
|
|
$
|
18,837
|
|
|
$
|
693
|
|
|
|
4
|
|
Product revenues
|
|
|
7,122
|
|
|
|
6,983
|
|
|
|
139
|
|
|
|
2
|
|
Royalty and license fee income
|
|
|
300
|
|
|
|
440
|
|
|
|
(140
|
)
|
|
|
(32
|
)
|
Total revenues
|
|
|
26,952
|
|
|
|
26,260
|
|
|
|
692
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services
|
|
|
11,730
|
|
|
|
11,052
|
|
|
|
678
|
|
|
|
6
|
|
Cost of product revenues
|
|
|
3,877
|
|
|
|
3,520
|
|
|
|
357
|
|
|
|
10
|
|
Research and development
|
|
|
812
|
|
|
|
483
|
|
|
|
329
|
|
|
|
68
|
|
Selling, general and administrative
|
|
|
11,070
|
|
|
|
11,218
|
|
|
|
(148
|
)
|
|
|
(1
|
)
|
Provision for uncollectible accounts receivable
|
|
|
779
|
|
|
|
679
|
|
|
|
100
|
|
|
|
15
|
|
Legal fee expense
|
|
|
1,700
|
|
|
|
370
|
|
|
|
1,330
|
|
|
|
359
|
|
Total operating costs and expenses
|
|
|
29,968
|
|
|
|
27,322
|
|
|
|
2,646
|
|
|
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(3,016
|
)
|
|
|
(1,062
|
)
|
|
|
(1,954
|
)
|
|
|
(184
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
185
|
|
|
|
79
|
|
|
|
106
|
|
|
|
134
|
|
Other
|
|
|
33
|
|
|
|
24
|
|
|
|
9
|
|
|
|
38
|
|
Foreign currency gain (loss)
|
|
|
800
|
|
|
|
(94
|
)
|
|
|
894
|
|
|
|
**
|
|
Loss before income taxes
|
|
$
|
(1,998
|
)
|
|
$
|
(1,053
|
)
|
|
$
|
(945
|
)
|
|
|
(90
|
)
|
** not meaningful
Consolidated Results:
The “2018 period” and the “2017 period”
refer to the three months ended January 31, 2018 and 2017, respectively.
Clinical laboratory services revenues for the 2018 period were
$19.5 million compared to $18.8 million in the 2017 period, an increase of $0.7 million or 4%. The increase is attributed to molecular
and women’s health testing volume in women’s health markets, the addition of new accounts, and expansion of the service
area versus the 2017 period, partially offset by weather related delays in testing experienced during the 2018 period.
Product revenues for the 2018 period were $7.1 million compared
to $7.0 million in the 2017 period, an increase of $0.1 million or 2%. The increase resulted from the positive impact of foreign
currency translation and organic growth in foreign markets, which was partially offset by lower product order volume in the United
States due to lower research funding and lower pricing due to competition.
The cost of clinical laboratory services during the 2018 period
was $11.7 million as compared to $11.0 million in the 2017 period, an increase of $0.7 million or 6% due to the volume increase
in clinical laboratory services revenue, from molecular testing, primarily for reagent costs and compensation expenses. Gross profit
margin was 40% in the 2018 period and 41% in the 2017 period.
The
cost of product revenues was $3.9 million in the 2018 period and $3.5 million in the 2017 period, an increase of $0.4 million or
10% primarily due to the sale of lower margin items and an increase in headcount. The gross profit margin on products was 45.6%
in the 2018 period and 49.6% in the 2017 period and was also impacted by price discounting.
Research and development expenses
were $0.8 million versus $0.5 million in the 2018 period, an increase of $0.3 million or 68%. The expense for the Life Sciences
segment increased $0.1 million due to compensation expenses. The expense for the Therapeutics
segment in the 2018 period increased $0.2 million due to the impact of an adjustment recorded in the 2017 period decreasing an
obligation for clinical trial activity.
Selling, general and administrative expenses were approximately
$11.1 million during the 2018 period versus $11.2 million during the 2017 period, a decrease of $0.1 million or 1%. The Clinical
Lab segment expense increased $0.2 million, primarily comprised of billing expenses. The Life Sciences segment expense was comparable
in both periods. The Other segment expense decreased $0.3 million, comprised of a decrease in compensation related expenses.
The provision for uncollectible accounts receivable, primarily
related to the Clinical Labs segment, was approximately $0.8 million in the 2018 period and $0.7 million in the 2017 period, an
increase of approximately $0.1 million. As a percentage of Clinical laboratory services, the provision for uncollectible accounts
receivable relating to the Clinical Labs segment was 4.1% in the 2018 period and 3.2% in the 2017 period.
Legal fee expense was $1.7 million during the 2018 period compared
to $0.4 million in the 2017 period, an increase of $1.3 million or 359% due to the timing of legal activity and related costs associated
with on-going litigation and contract dispute where the Company is the plaintiff.
Segment Results:
Clinical Labs
Revenue from laboratory services for the 2018 period were $19.5
million compared to $18.8 million in the 2017 period. The increase of $0.7 million or 4% is attributed to increased molecular and
women’s health testing volume and the addition of new accounts and expansion of the service area, partially offset by weather
related delays in testing experienced during the 2018 period. Cost of services during the 2018 period was $11.7 million as compared
to $11.0 million in the 2017 period, an increase of $0.7 million or 6% due to higher testing volume, primarily for reagent costs
and compensation expenses. Gross profit margin was 40% in the 2018 period and 41% in the 2017 period. As a percentage of revenues,
the provision for uncollectable accounts, primarily for self-pay patient accounts, was 4.1% for the 2018 period and 3.2% for the
2017 period. Income before taxes was $0.9 million for 2018 period as compared to $1.2 million in the 2017 period, a decrease of
$0.3 million.
Life Sciences
Product revenues for the 2018 period were $7.1 million compared
to $7.0 million in the 2017 period, an increase of $0.1 million or 2%. The increase resulted from the positive impact of foreign
currency translation, which was partially offset by lower product order volume in the United States due to lower research funding
and lower pricing due to competition. The segment’s gross profit was $3.5 million in the 2018 period and $3.9 million in
the 2017 period. The gross profit margin on products was 45.6% in the 2018 period and 49.6% in the 2017 period and was negatively
impacted by the sale of lower margin products, increase in headcount, and price discounting. Selling general and administrative
expenses were comparable in both periods. Research and development increased $0.1 million compared to the 2017 period. Due to significant
appreciation of foreign currencies versus the US dollar at the end of the 2018 period compared to the end of the 2017 period, in
particular the British pound, Euro and Swiss franc, the foreign currency gain was $0.8 million compared to a loss of $0.1 million
in the 2017 period, a favorable change of $0.9 million. Income before taxes was $0.9 million for the 2018 period as compared to
$0.3 million for the 2017 period, an increase of $0.6 million.
Therapeutics
The Therapeutics segment’s operating loss before income
taxes was approximately $0.2 million in the 2018 period. The segment was breakeven during the 2017 period due to the impact of
an adjustment decreasing an obligation for clinical trial activity.
Other
The Other segment’s operating loss before taxes for the
2018 period was approximately $3.5 million compared to $2.6 million for the 2017 period, an increase of $0.9 million. The 2018
period legal expense associated with on-going litigation and contract dispute increased $1.3 million. Compensation related expenses
decreased $0.3 million. Interest income increased $0.1 million due to the impact of a higher interest rate earned on cash and cash
equivalents during the 2018 period and because interest expense was incurred only in the 2017 period on a loan payable which was
then outstanding. The loan was repaid during the 2017 period.
Results of Operations
Six months ended January 31, 2018 compared
to January 31, 2017
(in 000s)
Comparative Financial Data for the Six Months Ended January
31,
|
|
2018
|
|
|
2017
|
|
|
Increase
(Decrease)
|
|
|
%
Change
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical laboratory services
|
|
$
|
39,864
|
|
|
$
|
37,395
|
|
|
$
|
2,469
|
|
|
|
7
|
|
Product revenues
|
|
|
14,203
|
|
|
|
14,409
|
|
|
|
(206
|
)
|
|
|
(1
|
)
|
Royalty and license fee income
|
|
|
561
|
|
|
|
740
|
|
|
|
(179
|
)
|
|
|
(24
|
)
|
Total revenues
|
|
|
54,628
|
|
|
|
52,544
|
|
|
|
2,084
|
|
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services
|
|
|
23,772
|
|
|
|
21,948
|
|
|
|
1,824
|
|
|
|
8
|
|
Cost of product revenues
|
|
|
7,266
|
|
|
|
6,829
|
|
|
|
437
|
|
|
|
6
|
|
Research and development
|
|
|
1,559
|
|
|
|
1,305
|
|
|
|
254
|
|
|
|
19
|
|
Selling, general and administrative
|
|
|
21,961
|
|
|
|
22,712
|
|
|
|
(751
|
)
|
|
|
(3
|
)
|
Provision for uncollectible accounts receivable
|
|
|
1,593
|
|
|
|
1,348
|
|
|
|
245
|
|
|
|
18
|
|
Legal fee expense
|
|
|
2,131
|
|
|
|
742
|
|
|
|
1,389
|
|
|
|
187
|
|
Total operating costs and expenses
|
|
|
58,282
|
|
|
|
54,884
|
|
|
|
3,398
|
|
|
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(3,654
|
)
|
|
|
(2,340
|
)
|
|
|
(1,314
|
)
|
|
|
(56
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
342
|
|
|
|
125
|
|
|
|
217
|
|
|
|
174
|
|
Other
|
|
|
69
|
|
|
|
143
|
|
|
|
(74
|
)
|
|
|
(52
|
)
|
Foreign currency gain (loss)
|
|
|
605
|
|
|
|
(455
|
)
|
|
|
1,060
|
|
|
|
**
|
|
Loss before income taxes
|
|
$
|
(2,638
|
)
|
|
$
|
(2,527
|
)
|
|
$
|
(111
|
)
|
|
|
(4
|
)
|
** not meaningful
Consolidated Results:
The “2018 period” and the “2017 period”
refer to the six months ended January 31, 2018 and 2017, respectively.
Clinical laboratory services revenues for the 2018 period were
$39.9 million compared to $37.4 million in the 2017 period, an increase of $2.5 million or 7%. The increase is attributed to molecular
and women’s health testing volume in women’s health markets, the addition of new accounts, and expansion of the service
area versus the 2017 period, partially offset by weather related delays in testing experienced during the 2018 period.
Product revenues for the 2018 period were $14.2 million compared
to $14.4 million in the 2017 period, a decrease of $0.2 million or 1%. The decrease resulted from lower product order volume due
to lower research funding and lower pricing due to competition in the United States, which was partially offset by organic growth
in foreign markets and the positive impact of foreign currency translation.
The cost of clinical laboratory services during the 2018 period
was $23.8 million as compared to $21.9 million in the 2017 period, an increase of $1.8 million or 8% due to the volume increase
in clinical laboratory services revenue from molecular testing, primarily for reagent costs, compensation expenses, and outside
reference testing. Gross profit margin was 40% in the 2018 period and 41% in the 2017 period
The cost of product revenues was $7.3 million in the 2018 period
and $6.8 million in the 2017 period, an increase of $0.4 million or 6% due to the sale of lower margin items and an increase in
headcount. The gross profit margin on products was 48.8% in the 2018 period and 52.6% in the 2017 period, and was also negatively
impacted by lower pricing due to competition.
Research and development expenses were $1.6 million versus $1.3
million in the 2018 period, an increase of $0.3 million or 19%. The expense for the Therapeutics segment was $0.5 million in the
2018 period and $0.2 million in the 2017 period. The lower expense in the 2017 period was due to the impact of an adjustment decreasing
an obligation for clinical trial activity. The expense for the Life Sciences segment was comparable in both periods.
Selling, general and administrative expenses were approximately
$22.0 million during the 2018 period versus $22.7 million during the 2017 period, a decrease of $0.7 million or 3%. The Clinical
Lab segment expense increased $0.3 million comprised of a $0.3 million increase in billing expenses and a $0.1 million increase
in information technology and bank fee expenses, partially offset by a decrease of $0.1 million in salary expenses, primarily for
commissions. The Life Sciences segment expense decreased $0.3 million due to a decrease in intangibles amortization. The Other
segment expense decreased $0.7 million, comprised of a decrease in compensation related expenses of $0.6 million and a decrease
of $0.1 million in professional fees and office expenses.
The provision for uncollectible accounts receivable, primarily
related to the Clinical Labs segment, was approximately $1.6 million in the 2018 period and $1.3 million in the 2017 period, an
increase of approximately $0.3 million. As a percentage of Clinical laboratory services, the provision for uncollectible accounts
receivable relating to the Clinical Labs segment was 4.0% in the 2018 period and 3.4% in the 2017 period.
Legal fee expense was $2.1 million during the 2018 period compared
to $0.7 million in the 2017 period, an increase of $1.4 million or 187% due to the timing of legal activity and related costs associated
with on-going litigation and contract dispute where the Company is the plaintiff.
Segment Results:
Clinical Labs
Revenue from laboratory services for the 2018 period were $39.9
million compared to $37.4 million in the 2017 period. The increase of $2.5 million or 7% is attributed to increased molecular and
women’s health testing volume and the addition of new accounts and expansion of the service area, partially offset by weather
related delays in testing during the 2018 period. Cost of services during the 2018 period was $23.8 million as compared to $21.9
million in the 2017 period, an increase of $1.8 million or 8% due to higher testing volume, primarily for reagent costs, compensation
expenses, and outside reference testing. Gross profit margin was 40% in the 2018 period and 41% in the 2017 period. As a percentage
of revenues, the provision for uncollectable accounts, primarily for self-pay patient accounts, was 4.0% for the 2018 period and
3.4% for the 2017 period. Income before taxes was $2.2 million for 2018 period as compared to $2.3 million in the 2017 period,
a decrease of $0.1 million.
Life Sciences
Product revenues for the 2018 period were $14.2 million compared
to $14.4 million in the 2017 period, a decrease of $0.2 million or 1%. The decrease resulted from lower product order volume in
the United States due to lower research funding and lower pricing due to competition, which was partially offset by organic growth
in foreign markets and the positive impact of foreign currency translation. The segment’s gross profit was $7.5 million in
the 2018 period and $8.3 million in the 2017 period, impacted by lower revenues, the sale of lower margin items and an increase
in headcount. The gross profit margin on products was 48.8% in the 2018 period and 52.6% in the 2017 period and was negatively
impacted by the sale of lower margin products and price discounting. In the 2018 period, selling general and administrative expenses
decreased $0.3 million compared to the 2017 period. Due to significant appreciation of foreign currencies versus the US dollar
at the end of the 2018 period compared to the end of the 2017 period, in particular the British pound. Euro and Swiss franc, the
foreign currency gain was $0.6 million compared to a loss of $0.5 million in the 2017 period, a favorable change of $1.1 million.
Income before taxes was $1.5 million for the 2018 period as compared to $0.8 million for the 2017 period, an increase of $0.7 million.
Therapeutics
The Therapeutics segment’s operating loss before income
taxes was approximately $0.4 million in the 2018 period and $0.2 million in the 2017 period. The lower expense during the 2017
period was due to the impact of an adjustment decreasing an obligation for clinical trial activity.
Other
The Other segment’s operating loss before taxes for the
2018 period was approximately $5.9 million compared to $5.4 million for the 2017 period, an increase of $0.5 million. During the
2018 period, legal fee expense associated with on-going litigation and contract dispute increased $1.5 million. The 2018 period
selling general and
administrative expense declined $0.7 million compared to the 2017
period due to decreases in compensation related expenses, and a $0.1 decrease in professional fees and office expense. Interest
income increased $0.2 million in the 2018 period due to the impact of a higher interest rate earned on cash and cash equivalents
and because interest expense was incurred only in the 2017 period on the loan payable then outstanding. The loan was repaid during
the second quarter of 2017 period..
Liquidity and Capital Resources
At January
31
,
2018, the Company had cash and cash equivalents of $64.5 million of which $0.5 million was in foreign accounts, as compared to
cash and cash equivalents of $64.2 million, of which $0.5 million was in foreign accounts at July 31, 2017. It is the Company’s
current intent to permanently reinvest these funds outside of the United States, and its current plans do not demonstrate a need
to repatriate them to fund its United States operations. The Company had working capital of $69.7 million at January
31
,
2018 compared to $71.3 million at July 31, 2017. The decrease in working capital of $1.6 million was primarily due to the period
loss and net changes in operating assets and liabilities.
Net cash provided by operating activities
as of January
31
, 2018 was approximately $0.8 million as compared to cash used in operating
activities of $2.8 million in fiscal 2017, an increase of approximately $3.6 million. The increase is due to net changes in assets
and liabilities of $3.7 million and decrease in net loss of $1.0 million offset by $1.1 million in non-cash adjustments.
Net cash used in investing activities in fiscal 2018 and 2017
was approximately $1.1 million and $0.7 million, respective, which consists primarily of capital expenditures.
Net cash provided by financing activities in fiscal 2018 was approximately
$0.5 million as compared to cash used in financing activities of $1.8 million in fiscal 2017. The change of $2.3 million is mainly
due to borrowings from the credit agreement of $1.6 million in the 2017 period and the exercise of stock options $0.7 million in
the 2018 period.
The Company believes that its current cash and cash equivalents
level, and utilization of the Controlled Equity Offering program if necessary, as disclosed in Form 10-K Note 10 to the financial
statements are sufficient for its foreseeable liquidity and capital resource needs over at least the next twelve (12) months, although
there can be no assurance that future events will not alter such view. Although there can be no assurances, in the event additional
capital is required, the Company believes it has the ability to raise additional funds through equity offerings or other sources.
Our liquidity plans are subject to a number of risks and uncertainties, including those described in the Item 1A. “Risk Factors”
section of our Form 10-K for the year ended July 31, 2017, some of which are outside our control. Macroeconomic conditions could
limit our ability to successfully execute our business plans and therefore adversely affect our liquidity plans.
Contractual Obligations
There have been no material changes to our Contractual Obligations
as reported in our Form 10-K for the fiscal year ended July 31, 2017.
Management is not aware of any material claims, disputes or settled
matters concerning third party reimbursement that would have a material effect on our financial statements, except as disclosed
in Note 11 to the Consolidated Financial Statements.
Off-Balance Sheet Arrangements
The Company does not have any “off-balance sheet arrangements”
as such term is defined in Item 303(a)(4) of Regulation S-K.
Critical Accounting Policies
The Company’s discussion and analysis of its financial condition
and results of operations are based upon Enzo Biochem, Inc.’s consolidated financial statements, which have been prepared
in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements
requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses.
These estimates and judgments also affect related disclosure of contingent assets and liabilities.
On an on-going basis, we evaluate our estimates, including those
related to contractual expense, allowance for uncollectible accounts, inventory, intangible assets and income taxes. The Company
bases its estimates on experience and on various other assumptions that are believed to be reasonable under the circumstances,
the results
of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions.
Product revenues
Revenues from product sales are recognized when the products are
shipped and title transfers, the sales price is fixed or determinable and collectability is reasonably assured.
Royalties
Royalty revenues are recorded in the period earned. Royalties
received in advance of being earned are recorded as deferred revenues.
Revenues – Clinical laboratory services
Revenues from Clinical Labs are recognized upon completion of
the testing process for a specific patient and reported to the ordering physician. These revenues and the associated accounts receivable
are based on gross amounts billed or billable for services rendered, net of a contractual adjustment, which is the difference between
amounts billed to payers and the expected approved reimbursable settlements from such payers.
The following table represents the clinical laboratory segment’s
net revenues and percentages by revenue category:
|
|
Three months ended
January 31, 2018
|
|
|
Three months ended
January 31, 2017
|
|
Revenue category
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Third-party payer
|
|
$
|
11,102
|
|
|
|
57
|
%
|
|
$
|
10,773
|
|
|
|
57
|
%
|
Patient self-pay
|
|
|
2,383
|
|
|
|
12
|
|
|
|
2,772
|
|
|
|
15
|
|
Medicare
|
|
|
3,230
|
|
|
|
17
|
|
|
|
2,796
|
|
|
|
15
|
|
HMO’s
|
|
|
2,815
|
|
|
|
14
|
|
|
|
2,496
|
|
|
|
13
|
|
Total
|
|
$
|
19,530
|
|
|
|
100
|
%
|
|
$
|
18,837
|
|
|
|
100
|
%
|
|
|
Six months ended
January 31, 2018
|
|
|
Six months ended
January 31, 2017
|
|
Revenue category
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Third-party payer
|
|
$
|
22,762
|
|
|
|
57
|
%
|
|
$
|
20,966
|
|
|
|
56
|
%
|
Patient self-pay
|
|
|
5,242
|
|
|
|
13
|
|
|
|
5,875
|
|
|
|
16
|
|
Medicare
|
|
|
6,215
|
|
|
|
16
|
|
|
|
5,631
|
|
|
|
15
|
|
HMO’s
|
|
|
5,645
|
|
|
|
14
|
|
|
|
4,923
|
|
|
|
13
|
|
Total
|
|
$
|
39,864
|
|
|
|
100
|
%
|
|
$
|
37,395
|
|
|
|
100
|
%
|
The Company provides services to certain patients covered by various
third-party payers, including the Federal Medicare program. Laws and regulations governing Medicare are complex and subject to
interpretation for which action for noncompliance includes fines, penalties and exclusion from the Medicare programs.
Other than the Medicare program, one provider whose programs are
included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”)
categories represents approximately 38% and 39% of the Clinical Labs segment net revenue for the three months ended January 31,
2018 and 2017 respectively, and 39% and 37% for the six months ended January 31, 2018 and 2017, respectively.
Contractual Adjustment
The Company’s estimate of contractual adjustment is based
on significant assumptions and judgments, such as its interpretation of payer reimbursement policies, and bears the risk of change.
The estimation process is based on the experience of amounts approved as reimbursable and ultimately settled by payers, versus
the corresponding gross amount billed to the respective payers. The contractual adjustment is an estimate that reduces gross revenue,
based on gross billing rates, to amounts expected to be approved and reimbursed. Gross billings are based on a standard fee schedule
we set for all third party payers, including Medicare, HMO’s and managed care. The Company adjusts the contractual adjustment
estimate quarterly, based on its evaluation of current and historical settlement experience with payers, industry reimbursement
trends, and other relevant factors.
The other relevant factors that affect our contractual adjustment
include the monthly and quarterly review of: 1) current gross billings and receivables and reimbursement by payer, 2) current changes
in third party arrangements and 3) the growth of in-network provider arrangements and managed care plans specific to our Company.
Our clinical laboratory business is primarily dependent upon reimbursement
from third-party payers, such as Medicare (which principally serves patients 65 and older) and insurers. We are subject to variances
in reimbursement rates among different third-party payers, as well as constant changes of reimbursement rates. Changes that decrease
reimbursement rates or coverage would negatively impact our revenues. The number of individuals covered under managed care contracts
or other similar arrangements has grown over the past several years and may continue to grow in the future. In addition, Medicare
and other government healthcare programs continue to shift to managed care. These trends will continue to reduce our revenues from
these programs.
During the three months ended January 31, 2018 and 2017, the contractual
adjustment percentages, determined using current and historical reimbursement statistics, were 84.1% and 82.8%, respectively, of
gross billings. During the six months ended January 31, 2018 and 2017, the contractual adjustment percentages, determined using
current and historical reimbursements statistics, were 84.5% and 83.4%, respectively. In general, the Company believes a decline
in reimbursement rates or a shift to managed care or similar arrangements may be offset by the positive impact of an increase in
the number of molecular tests we perform. However, there can be no assurance that we can increase the number of tests we perform
or that if we do increase the number of tests we perform, that we can maintain that higher number of tests performed, or that an
increase in the number of tests we perform would result in increased revenue.
The Company estimates (by using a sensitivity analysis) that each
1% point change in the contractual adjustment percentage could result in a change in clinical laboratory services revenues of approximately
$2.6 million and $2.3 million for the six months ended January 31, 2018 and 2017, respectively, and a change in the net accounts
receivable of approximately $0.6 million as of January 31, 2018.
Our clinical laboratory financial billing system records gross
billings using a standard fee schedule for all payers and does not record contractual adjustment by payer at the time of billing.
Therefore, we are unable to quantify the effect contractual adjustments recorded during the current period have on revenue recorded
in a previous period. However, we can reasonably estimate our monthly contractual adjustment to revenue on a timely basis based
on our quarterly review process, which includes:
•
|
an analysis of industry reimbursement trends;
|
|
|
•
|
an evaluation of third-party reimbursement rates changes and changes in reimbursement arrangements with third-party payers;
|
|
|
•
|
a rolling monthly analysis of current and historical claim settlement and reimbursement experience statistics with payers; and
|
|
|
•
|
an analysis of current gross billings and receivables by payer.
|
Accounts Receivable and Allowance for Doubtful Accounts
Accounts receivable are reported at realizable value, net of allowances
for doubtful accounts, which is estimated and recorded in the period of the related revenue.
The following is a table of the Company’s net accounts receivable
by segment. The Clinical Labs segment’s net receivables are detailed by billing category and as a percent to its total net
receivables. At January 31, 2018, and July 31, 2017, approximately 73%, of the Company’s net accounts receivable relates
to its Clinical Labs business, which operates in the New York, New Jersey and Connecticut medical communities.
The Life Sciences segment’s accounts
receivable balance includes $1.3 million or 32% and $1.1 million or 29% of foreign receivables as of January 31, 2018 and
July 31, 2017, and includes royalty receivables of $0.4 and $0.4 million, as of January 31, 2018 and July 31, 2017,
respectively, from its licensee Qiagen.
Net accounts receivable
Billing category
|
|
As of
January 31, 2018
|
|
|
As of
July 31, 2017
|
|
Clinical Labs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Third party payers
|
|
$
|
7,218
|
|
|
|
66
|
%
|
|
$
|
7,256
|
|
|
|
64
|
%
|
Medicare
|
|
|
1,730
|
|
|
|
16
|
|
|
|
1,385
|
|
|
|
12
|
|
HMO’s
|
|
|
1,181
|
|
|
|
11
|
|
|
|
1,169
|
|
|
|
10
|
|
Patient self-pay
|
|
|
788
|
|
|
|
7
|
|
|
|
1,591
|
|
|
|
14
|
|
Total Clinical Labs
|
|
|
10,917
|
|
|
|
100
|
%
|
|
|
11,401
|
|
|
|
100
|
%
|
Total Life Sciences
|
|
|
4,060
|
|
|
|
|
|
|
|
3,779
|
|
|
|
|
|
Total accounts receivable
|
|
$
|
14,977
|
|
|
|
|
|
|
$
|
15,180
|
|
|
|
|
|
Changes in the Company’s allowance for doubtful accounts
are as follows:
|
|
Six months ended
January 31, 2018
|
|
|
Fiscal year ended
July 31, 2017
|
|
Beginning balance
|
|
$
|
3,576
|
|
|
$
|
3,517
|
|
Provision for doubtful accounts
|
|
|
1,593
|
|
|
|
2,775
|
|
Write-offs, net
|
|
|
(1,383
|
)
|
|
|
(2,716
|
)
|
Ending balance
|
|
$
|
3,786
|
|
|
$
|
3,576
|
|
For the Clinical Labs segment, the allowance for doubtful accounts
represents amounts that the Company does not expect to collect after the Company has exhausted its collection procedures. The Company
estimates its allowance for doubtful accounts in the period the related services are billed and reduces the allowance in future
accounting periods based on write-offs during those periods. The Company bases the estimate for the allowance on the evaluation
of historical experience of accounts going to collections and the net amounts not received. Accounts going to collection include
the balances, after receipt of the approved settlements from third party payers, for the insufficient diagnosis information received
from the ordering physician which result in denials of payment and our estimate of the uncollected portion of receivables from
self-payers, including deductibles and copayments, which are subject to credit risk and patients’ ability to pay. The Company
fully reserves through its contractual allowances amounts that have not been written off because the payer’s filing date
deadline has not occurred or the collection process has not been exhausted. The Company adjusts the historical collection analysis
for recoveries, if any, on an on-going basis.
The Company’s ability to collect outstanding receivables
from third party payers is critical to its operating performance and cash flows. The primary collection risk lies with uninsured
patients or patients for whom primary insurance has paid but a patient portion remains outstanding. The Company also assesses the
current state of its billing functions in order to identify any known collection or reimbursement issues in order to assess the
impact, if any, on the allowance estimates, which involves judgment.
The Company believes that the collectability of its receivables
is directly linked to the quality of its billing processes, most notably, those related to obtaining the accurate patient information
in order to bill effectively for the services provided. Should circumstances change (e.g. shift in payer mix, decline in economic
conditions or deterioration in aging of receivables), our estimates of net realizable value of receivables could be reduced by
a material amount.
Billing for laboratory services is complicated because of many
factors, especially: the differences between our standard gross fee schedule for all payers and the reimbursement rates of the
various payers we deal with, disparity of coverage and information requirements among the various payers, and disputes with payers
as to which party is responsible for reimbursement. The allowance for doubtful accounts as a percentage of total accounts receivable
at January 31, 2018 and July 31, 2017 was 20.2% and 19.1%, respectively.
The following table indicates the Clinical Labs aged gross receivables
by payer group which is prior to adjustment to gross receivables for: 1) contractual adjustment, 2) fully reserved balances not
yet written off, and 3) other revenue adjustments.
As of January 31, 2018
|
|
Total
|
|
|
%
|
|
|
Third
Party
Payers
|
|
|
%
|
|
|
Self-Pay
|
|
|
%
|
|
|
Medicare
|
|
|
%
|
|
|
HMO’s
|
|
|
%
|
|
1-30 days
|
|
$
|
27,330
|
|
|
|
46
|
|
|
$
|
18,242
|
|
|
|
44
|
|
|
$
|
1,125
|
|
|
|
19
|
|
|
$
|
4,414
|
|
|
|
56
|
|
|
$
|
3,549
|
|
|
|
92
|
|
31-60 days
|
|
|
6,536
|
|
|
|
11
|
|
|
|
4,515
|
|
|
|
11
|
|
|
|
873
|
|
|
|
14
|
|
|
|
974
|
|
|
|
12
|
|
|
|
174
|
|
|
|
5
|
|
61-90 days
|
|
|
4,973
|
|
|
|
9
|
|
|
|
3,326
|
|
|
|
8
|
|
|
|
806
|
|
|
|
13
|
|
|
|
806
|
|
|
|
10
|
|
|
|
35
|
|
|
|
1
|
|
91-120 days
|
|
|
4,580
|
|
|
|
8
|
|
|
|
3,128
|
|
|
|
8
|
|
|
|
734
|
)
|
|
|
12
|
|
|
|
710
|
|
|
|
9
|
|
|
|
8
|
|
|
|
—
|
|
121-150 days
|
|
|
3,563
|
|
|
|
6
|
|
|
|
2,453
|
|
|
|
6
|
|
|
|
577
|
|
|
|
10
|
|
|
|
521
|
|
|
|
7
|
|
|
|
12
|
|
|
|
—
|
|
Greater than 150 days
|
|
|
12,053
|
|
|
|
20
|
|
|
|
9,545
|
|
|
|
23
|
|
|
|
1,955
|
)
|
|
|
32
|
|
|
|
464
|
|
|
|
6
|
|
|
|
89
|
|
|
|
2
|
|
Totals
|
|
$
|
59,035
|
|
|
|
100
|
%
|
|
$
|
41,209
|
|
|
|
100
|
%
|
|
$
|
6,070
|
|
|
|
100
|
%
|
|
$
|
7,889
|
|
|
|
100
|
%
|
|
$
|
3,867
|
|
|
|
100
|
%
|
As of July 31, 2017
|
|
Total
|
|
|
%
|
|
|
Third
Party
Payers
|
|
|
%
|
|
|
Self-Pay
|
|
|
%
|
|
|
Medicare
|
|
|
%
|
|
|
HMO’s
|
|
|
%
|
|
1-30 days
|
|
$
|
25,357
|
|
|
|
42
|
|
|
$
|
16,683
|
|
|
|
40
|
|
|
$
|
1,082
|
|
|
|
16
|
|
|
$
|
4,022
|
|
|
|
60
|
|
|
$
|
3,570
|
|
|
|
82
|
|
31-60 days
|
|
|
8,732
|
|
|
|
15
|
|
|
|
5,723
|
|
|
|
14
|
|
|
|
1,183
|
|
|
|
17
|
|
|
|
1,294
|
|
|
|
19
|
|
|
|
532
|
|
|
|
12
|
|
61-90 days
|
|
|
5,703
|
|
|
|
10
|
|
|
|
4,208
|
|
|
|
10
|
|
|
|
927
|
|
|
|
14
|
|
|
|
529
|
|
|
|
9
|
|
|
|
39
|
|
|
|
1
|
|
91-120 days
|
|
|
3,749
|
|
|
|
6
|
|
|
|
2,732
|
|
|
|
6
|
|
|
|
701
|
|
|
|
10
|
|
|
|
288
|
|
|
|
4
|
|
|
|
28
|
|
|
|
1
|
|
121-150 days
|
|
|
3,689
|
|
|
|
6
|
|
|
|
2,772
|
|
|
|
7
|
|
|
|
672
|
|
|
|
10
|
|
|
|
228
|
|
|
|
3
|
|
|
|
17
|
|
|
|
—
|
|
Greater than 150 days
|
|
|
12,455
|
|
|
|
21
|
|
|
|
9,652
|
|
|
|
23
|
|
|
|
2,270
|
|
|
|
33
|
|
|
|
379
|
|
|
|
5
|
|
|
|
154
|
|
|
|
4
|
|
Totals
|
|
$
|
59,685
|
|
|
|
100
|
%
|
|
$
|
41,770
|
|
|
|
100
|
%
|
|
$
|
6,835
|
|
|
|
100
|
%
|
|
$
|
6,740
|
|
|
|
100
|
%
|
|
$
|
4,340
|
|
|
|
100
|
%
|
Income Taxes
The Company accounts for income taxes under the liability method
of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax
consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and
their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards
and other items be reduced by a valuation allowance where it is not more likely than not the benefits will be realized in the foreseeable
future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
It is the Company’s policy to provide for uncertain tax
positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely
than not to be sustained upon examination by tax authorities. To the extent the Company prevails in matters for which a liability
for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, the Company’s effective
tax rate in a given financial statement period may be affected.
Inventory
The Company values inventory at the lower of cost (first-in, first-out)
or net realizable value, which approximates market. Work-in-process and finished goods inventories consist of material, labor,
and manufacturing overhead. Write downs of inventories to net realizable value are based on a review of inventory quantities on
hand and estimated sales forecasts based on sales history and anticipated future demand. Unanticipated changes in demand could
have a significant impact on the value of our inventory and require additional write downs of inventory which would impact our
results of operations.
Goodwill and Intangible Assets
Goodwill represents the excess of the cost of an acquisition over
the fair value of the net assets acquired. Intangible assets, arose primarily from acquisitions, and primarily consist of customer
relationships, trademarks, licenses, and website and database content. Finite-lived intangible assets are amortized according to
their estimated useful lives, which range from 4 to 15 years.
The Company tests goodwill and long-lived assets annually
as of the first day of the fourth quarter, or more frequently if indicators of potential impairment exist. In assessing
goodwill and long-lived assets for impairment, the Company has the option to perform a qualitative assessment to determine
whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value
of a reporting unit is less than its carrying amount. If the Company determines that it is not more likely than not that the
fair value of a reporting unit is less than its carrying amount, the Company is not required to perform a quantitative test
in assessing goodwill and long-lived assets for impairment. However, if the Company concludes otherwise or elects not to
perform the qualitative assessment, then it identifies the reporting units and compares the fair value of each of these
reporting units to their respective carrying amount. If the carrying amount of the reporting unit is less than its fair
value, no impairment exists. If the carrying amount of the reporting unit is higher than its fair value, the impairment
charge is the amount by which the carrying amount exceeds its fair value, not to exceed the total amount of goodwill and
intangibles allocated to the reporting unit.